Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.035
0.00 (0.00%)
Jun 25, 2025, 10:31 AM - Market open
Ocugen Revenue
Ocugen had revenue of $1.48M in the quarter ending March 31, 2025, with 46.06% growth. This brings the company's revenue in the last twelve months to $4.52M, down -31.56% year-over-year. In the year 2024, Ocugen had annual revenue of $4.05M, down -32.82%.
Revenue (ttm)
$4.52M
Revenue Growth
-31.56%
P/S Ratio
64.02
Revenue / Employee
$47,600
Employees
95
Market Cap
302.25M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
OCGN News
- 2 days ago - Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases - GlobeNewsWire
- 6 days ago - Ocugen: Three Potential Gene-Therapy Filings By 2028 - Seeking Alpha
- 9 days ago - Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - GlobeNewsWire
- 14 days ago - Ocugen To Present at BIO International Convention 2025 - GlobeNewsWire
- 20 days ago - Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - GlobeNewsWire
- 4 weeks ago - Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - GlobeNewsWire
- 6 weeks ago - Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Ocugen Provides Business Update with First Quarter 2025 Financial Results - GlobeNewsWire